DOCSLIB.ORG

Atpase, Na+/K+ Transporting, Alpha 3 Polypeptide Homologous to 3'UTR

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atpase, Na+/K+ Transporting, Alpha 3 Polypeptide Homologous to 3'UTR HUGO ID Name Nalm-6 TOM-1 Reh Karpas-422 DoHH -2 SU-DHL-5 Namalwa DG-75 Ramos Raji BEL EHEB BONNA-12 L-428 DEL BCP-1 BC-3 BCBL-1 JSC-1 PEL-SY HBL-6 DS-1 RPMI-8226 NCI-H929 L-363 SK-MM-2 ATP1A3 ATPase, Na+/K+ transporting, alpha 3 polypeptide CD24 homologous to 3'UTR of human CD24 gene ABCC5 multidrug resistance-associated protein (MRP5) CD72 CD72 antigen TCL1A Tcell leukemia/lymphoma 1 ITGB2 Integrin, beta 2 (antigen CD18 (p95)) ? nuclear ribonucleoprotein particle (hnRNP) SGT1 suppressor of G2 allele of skp1 homolog DNMT 1 DNA (cytosine-5-)-methyltransferase 1 GALE UDP-Galactose 4 epimerase (GALE) HADHSC L-3-hydroxyacyl-CoA dehydrogenase LIG4 DNA ligase IV LIG1 Ligase I, DNA, ATP-dependent CEBPG CCAA T/enhancer binding protein (C/EBP), gamma DCK Deoxycytidine kinase TCEA1 TRANSCRIPTION ELONGATION FACTOR S-II TCN 1 TRANSCOBALAMIN I PRECURSOR POLA2 DNA polymerase alpha subunit CCNG2 cyclin G2 RNPC1 Finkel-Biskis-Reilly murine sarcoma virus; Human seb4D RNPC1 Finkel-Biskis-Reilly murine sarcoma virus; Human seb4D DGKD Diacylglycerol kinase delta KIAA0220 Polycystic kidney disease protein 1 KIAA0220 calcium-dependent group X phospholipase A2 KIAA0220 calcium-dependent group X phospholipase A2 ALDH5A1 NAD+-dependent succinate-semialdehyde dehydrogenase CCNG2 Polycystic kidney disease 1 (autosomal dominant) PDCD4 nuclear antigen H731-like protein SSH3BP1 eps8 binding protein e3B1 MAP4K2 B lymphocyte serine/threonine protein kinase (GC kinase) MAPRE2 novel T-cell activation protein ZNFN1A Ikaros/LyF-1 homolog (hIk-1) FLJ22624 clone 23799 KIAA0355 KIAA0355 SFRS11 arginine-rich nuclear protein ELF1 ETS-RELATED TRANSCRIPTION FACTOR ELF-1 WEE1 WEE1-LIKE PROTEIN KINASE WEE1 similar to gb:X62048_cds1 WEE1-LIKE PROTEIN KINASE LRMP lymp hoid-restricted membrane protein (Jaw1) * HLCS Holocarboxylase synthetase ligase OSBPL10 Weakly similar to similar to oxysterol-binfing proteins BCL6 B cell lymphoma protein 6 (zinc finger protein 51) * ALOX5 Arachidonate 5-lipoxygenase SIAT1 Sialyltransferase 1 (beta-galactoside alpha-2,6-sialytransferase) CD79A Immunoglobulin-associated alpha CD22 CD22 antigen RBL1 Retinoblastoma-associated protein-like 107 KD SCP2 Sterol carrier protein 2 PLEK PLECKSTRIN HLA-DOB MHC class II protein HLA-DO beta chain STX7 syntaxin 7 ARHGEF7 KIAA0142 ? clone 23815 ICSBP1 Interferon consensus sequence binding protein UVRAG mRNA; UV Radiation Resistance Associated (UVRAG) NCOA 3 similar to TR:G1314285 G1314285 GRIP1 (AIB1) NCOA 3 Amplified in Breast Cancer (AIB1) NCOA 3 Amplified in Breast Cancer (AIB1) IL4R Interleukin 4 receptor ARHGEF6 KIAA0006 AIP immunophilin homolog ARA9 mRNA, complete cds LTBP1 Latent transforming growth factor beta binding protein 1 POLH xeroderma pigmentosum variant RAD30 PRKAR2B Protein kinase, cAMP-dependent, regulatory, type II, beta UCP3 Uncoupling protein 3 (mitochondrial, proton carrier) VIL2 Villin 2 (ezrin) UCH L1 Ubiquitin carbbboxyl-terminal hydrolase isozyme L1 BMP7 Bone morphogenetic protein 7 precursor SEC14L1 SEC14 (S. cerevisiae)-like EIF2S2 translational initiation factor 2 beta subunit (eIF-2-beta) EIF2S2 translational initiation factor 2 beta subunit (eIF-2-beta) RB1 Retinoblastoma 1 (including osteosarcoma) TRIP3 thyroid receptor interactor (TRIP3) mRNA PCM1 autoantigen pericentriol material 1 (PCM-1) NUP88 Nup88 protein GSTP1 Glutathione-S-transferase pi-1 ARHGDIB GDP-dissociation inhibitor protein (Ly-GDI) PTPRC Protein tyrosine phosphatase, receptor type, c (CD45) RNT RE Ribosomal protein S17 PLCG2 Phospholipase C, gamma 2 (phosphatidylinositol-specific) ALOX5AP 5-LIPOXYGENASE ACTIVA TING PROTEIN TA L1 T-cell acute lymphocytic leukemia 1 SYK Spleen tyrosine kinase RFC1 DNA-binding protein (PO-GA) ATP2A2 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 PDCD2 similar to TR:Q16342 PROGRAMMED CELL DEATH-2 KIAA0326 KIAA0326 TA NK TRAF family member-associated NFKB activator HRB hematopoietic progenitor kinase (HPK1) IGHM Immunoglobulin mu NA B2 transcription factor IL-4 Stat mRNA EDR2 polyhomeotic 2 homolog (HPH2).
Load more

Recommended publications
  • PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than Cd79a and Selective Association with T(8;21)-Acute Myelogenous Leukemia
    [CANCER RESEARCH 64, 7399–7404, October 15, 2004] PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than CD79a and Selective Association with t(8;21)-Acute Myelogenous Leukemia Enrico Tiacci,1 Stefano Pileri,2 Annette Orleth,1 Roberta Pacini,1 Alessia Tabarrini,1 Federica Frenguelli,1 Arcangelo Liso,3 Daniela Diverio,4 Francesco Lo-Coco,5 and Brunangelo Falini1 1Institutes of Hematology and Internal Medicine, University of Perugia, Perugia, Italy; 2Unit of Hematopathology, University of Bologne, Bologne, Italy; 3Section of Hematology, University of Foggia, Foggia, Italy; 4Department of Cellular Biotechnologies and Hematology, University La Sapienza of Rome, Rome, Italy; and 5Department of Biopathology, University Tor Vergata of Rome, Rome, Italy ABSTRACT (13, 16). PAX5 expression also occurs in the adult testis and in the mesencephalon and spinal cord during embryogenesis (17), suggesting an The transcription factor PAX5 plays a key role in the commitment of important role in the development of these tissues. hematopoietic precursors to the B-cell lineage, but its expression in acute Rearrangement of the PAX5 gene through reciprocal chromosomal leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and mye- translocations has been described in different types of B-cell malig- loid (AMLs) origin with a specific anti-PAX5 monoclonal antibody. Blasts nancies (18–23), and, more recently, PAX5 has also been shown to be from 150 B-cell ALLs showed strong PAX5 nuclear expression, paralleling targeted by aberrant hypermutation in Ͼ50% of diffuse large B-cell that of CD79a in the cytoplasm. Conversely, PAX5 was not detected in 50 lymphomas (24).
    [Show full text]
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model
    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • CD Markers Are Routinely Used for the Immunophenotyping of Cells
    ptglab.com 1 CD MARKER ANTIBODIES www.ptglab.com Introduction The cluster of differentiation (abbreviated as CD) is a protocol used for the identification and investigation of cell surface molecules. So-called CD markers are routinely used for the immunophenotyping of cells. Despite this use, they are not limited to roles in the immune system and perform a variety of roles in cell differentiation, adhesion, migration, blood clotting, gamete fertilization, amino acid transport and apoptosis, among many others. As such, Proteintech’s mini catalog featuring its antibodies targeting CD markers is applicable to a wide range of research disciplines. PRODUCT FOCUS PECAM1 Platelet endothelial cell adhesion of blood vessels – making up a large portion molecule-1 (PECAM1), also known as cluster of its intracellular junctions. PECAM-1 is also CD Number of differentiation 31 (CD31), is a member of present on the surface of hematopoietic the immunoglobulin gene superfamily of cell cells and immune cells including platelets, CD31 adhesion molecules. It is highly expressed monocytes, neutrophils, natural killer cells, on the surface of the endothelium – the thin megakaryocytes and some types of T-cell. Catalog Number layer of endothelial cells lining the interior 11256-1-AP Type Rabbit Polyclonal Applications ELISA, FC, IF, IHC, IP, WB 16 Publications Immunohistochemical of paraffin-embedded Figure 1: Immunofluorescence staining human hepatocirrhosis using PECAM1, CD31 of PECAM1 (11256-1-AP), Alexa 488 goat antibody (11265-1-AP) at a dilution of 1:50 anti-rabbit (green), and smooth muscle KD/KO Validated (40x objective). alpha-actin (red), courtesy of Nicola Smart. PECAM1: Customer Testimonial Nicola Smart, a cardiovascular researcher “As you can see [the immunostaining] is and a group leader at the University of extremely clean and specific [and] displays Oxford, has said of the PECAM1 antibody strong intercellular junction expression, (11265-1-AP) that it “worked beautifully as expected for a cell adhesion molecule.” on every occasion I’ve tried it.” Proteintech thanks Dr.
    [Show full text]
  • Recent Advances in Diagnosis, Prognosis and Biology of Small B Cell Lymphomas
    Turk J Hematol 2006; 23:173-181 REVIEW ARTICLE © Turkish Society of Hematology Recent advances in diagnosis, prognosis and biology of small B cell lymphomas Gülşah Kaygusuz, Işınsu Kuzu Department of Pathology, Ankara University, Faculty of Medicine, Ankara, Turkey [email protected] INTRODUCTION eral blood, bone marrow, and/or lymph nodes. Small B cell lymphomas are mature B cell lym- The term SLL is used for non-leukemic cases phoid neoplasms arising from the various differ- having the morphology and immunophenotype entiation stages of B cell development. Although of CLL. Many cases of CLL/SLL are thought to in the World Health Organization (WHO) classi- correspond to the recirculating naïve B cells. fication of lymphomas, they are described based Cases that show Ig gene variable region muta- on their morphology, phenotype and genetics, the tions may correspond to a subset of memory B differential diagnosis can be difficult because of cells [1]. some overlapping characteristics. Differences ob- served in the clinical outcome of cases represent- The nodal presentation of CLL/SLL is char- ing the same entity have also made it difficult to acterized by the diffuse infiltration of small lym- understand fully the biology of the small B cell phocytes admixed with prolymphocytes and lymphomas, but interpretation of the results of para-immunoblasts, giving rise to proliferation molecular profiling studies has helped patholo- centers or pseudofollicles. CLL/SLL cells are gists and clinicians in this regard. Some specific small lymphocytes with round nucleus, clumped genetic changes defined on the neoplastic B cells chromatin and scant cytoplasm. Nucleoli are have revealed the route of lymphomagenesis.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,005,612 B2 Ledbetter Et Al
    US009005612B2 (12) United States Patent (10) Patent No.: US 9,005,612 B2 Ledbetter et al. (45) Date of Patent: *Apr. 14, 2015 (54) BINDING DOMAIN-IMMUNOGLOBULIN 5,455,030 A 10/1995 Ladner et al. FUSION PROTEINS $599. A 3: BestInsley et al. al. (75) Inventors: Jeffrey A. Ledbetter, Seattle, WA (US); 5,530,101 A 6/1996 Queen et al. Martha S. Hayden-Ledbetter, Seattle, 5,580,756. A 12/1996 Linsley et al. WA (US) 5,595,7215,585,089 A 1431/1997 SAS,Kaminski et al.1 (73) Assignee: Emergent Product Development 5,597,707 A 1/1997 Marken et al. Seattle, LLC, Seattle, WA (US) 3.W - A 3.87 EaCee ea. (*) Notice: Subject to any disclaimer, the term of this 5,645,835 A 7/1997 Fell, Jr. et al. patent is extended or adjusted under 35 $22.9 A ck 8. 3. Earl 530,387.1 U.S.C. 154(b) by 0 days. 5,693,762.w A 12/1997 QueenOCC et Cal. al. ............ This patent is Subject to a terminal dis- 5,709,859 A 1/1998 Aruffo et al. claimer 5,714,147 A 2, 1998 Capon et al. 5,721, 108 A 2f1998 Robinson et al. (21) Appl. No.: 13/451,641 5,736,137 A 4, 1998 Anderson et al. 5,770,197 A 6/1998 Linsley et al. (22) Filed: Apr. 20, 2012 5,773.253 A 6/1998 Linsley et al. O O 5,776.456 A 7/1998 Anderson et al. (65) Prior Publication Data 5,795,572 A 8/1998 Diegel et al.
    [Show full text]
  • Anti-CD18 / LFA1 Beta Antibody (ARG41484)
    Product datasheet [email protected] ARG41484 Package: 100 μl anti-CD18 / LFA1 beta antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes CD18 / LFA1 beta Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P, WB Host Rabbit Clonality Polyclonal Isotype IgG Target Name CD18 / LFA1 beta Antigen Species Human Immunogen Recombinant protein of Human CD18 / LFA1 beta. Conjugation Un-conjugated Alternate Names MF17; LAD; CD antigen CD18; MFI7; MAC-1; Cell surface adhesion glycoproteins LFA-1/CR3/p150,95 subunit beta; LCAMB; Integrin beta-2; Complement receptor C3 subunit beta; LFA-1; CD18 Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 WB 1:500 - 1:2000 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Positive Control Mouse thymus Calculated Mw 85 kDa Observed Size ~ 98 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw www.arigobio.com 1/3 cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. Bioinformation Gene Symbol ITGB2 Gene Full Name integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) Background This gene encodes an integrin beta chain, which combines with multiple different alpha chains to form different integrin heterodimers.
    [Show full text]
  • CD79A Polyclonal ANTIBODY
    For Research Use Only CD79A Polyclonal ANTIBODY www.ptglab.com Catalog Number:22349-1-AP Basic Information Catalog Number: GenBank Accession Number: Recommended Dilutions: 22349-1-AP BC113733 WB 1:500-1:2000 Size: GeneID (NCBI): IHC 1:20-1:200 45 μg/150 μl 973 Source: Full Name: Rabbit CD79a molecule, immunoglobulin-associated Isotype: alpha IgG Calculated MW: Purification Method: 226aa,25 kDa Antigen affinity purification Observed MW: Immunogen Catalog Number: 38-42 kDa AG17924 Applications Tested Applications: Positive Controls: IHC, WB, ELISA WB : Daudi cells; Raji cells, Ramos cells Species Specificity: IHC : human tonsillitis tissue; human Note: suggested angen retrieval with TE buffer pH 9.0; (*) Alternavely, angen retrieval may be performed with citrate buffer pH 6.0 CD79A, also named as B-cell antigen receptor complex-associated protein alpha chain or MB-1 membrane glycoprotein, is a 226 amino acid protein, which Background Information contains one ITAM domain and one Ig-like C2-type (immunoglobulin-like) domain. CD79A is expressed in B cell and localizes in the cell membrane. CD79A is required in cooperation with CD79B for initiation of the signal transduction cascade activated by binding of antigen to the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. CD79A is also required for BCR surface expression and for efficient differentiation of pro- and pre-B-cells. Notable Publications Author Pubmed ID Journal Application Storage: Storage Store at -20ºC. Stable for one year after shipment. Storage Buffer: PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
    [Show full text]
  • Rabbit Anti-Phospho-CD18-SL10462R-FITC
    SunLong Biotech Co.,LTD Tel: 0086-571- 56623320 Fax:0086-571- 56623318 E-mail:[email protected] www.sunlongbiotech.com Rabbit Anti-Phospho-CD18 SL10462R-FITC Product Name: Anti-Phospho-CD18 (Thr758)/FITC Chinese Name: FITC标记的磷酸化整合素β2/Integrin β2抗体 CD18 (Phospho Thr758); CD18 (Phospho-Thr758); CD18 (Phospho T758); p-CD18 (T758); p-CD18 (Thr758); Integrin beta 2; 95 subunit beta; CD 18; CD18; Cell surface adhesion glycoprotein LFA 1/CR3/P150,959 beta subunit precursor); Cell surface adhesion glycoproteins LFA 1/CR3/p150,95 subunit beta; Cell surface adhesion glycoproteins LFA-1/CR3/p150; Complement receptor C3 beta subunit; Complement Alias: receptor C3 subunit beta; Integrin beta chain beta 2; Integrin beta-2; Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit); ITB2_HUMAN; ITGB2; LAD; LCAMB; Leukocyte associated antigens CD18/11A, CD18/11B, CD18/11C; Leukocyte cell adhesion molecule CD18; LFA 1; LFA1; Lymphocyte function associated antigen 1; MAC 1; MAC1; MF17; MFI7; OTTHUMP00000115278; OTTHUMP00000115279; OTTHUMP00000115280; OTTHUMP00000115281; OTTHUMP00000115282. Organism Species: Rabbit Clonality: Polyclonal React Species: Human,Mouse,Rat,Chicken,Dog,Pig,Cow,Horse,Rabbit,Sheep,Guinea Pig, Flow-Cyt=1:50-200ICC=1:50-200IF=1:50-200www.sunlongbiotech.com Applications: not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. Molecular weight: 82kDa Form: Lyophilized or Liquid Concentration: 1mg/ml KLH conjugated synthesised phosphopeptide derived from human CD18 around the immunogen: phosphorylation site of Thr758 Lsotype: IgG Purification: affinity purified by Protein A Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Store at -20 °C for one year.
    [Show full text]
  • Immuno-Oncology Panel 4 (Direct-MRM MS, Pending)
    Immuno-Oncology panel 4 (direct-MRM MS, pending) (397 analytes pending validation) Gene Symbol Target protein name UniProt ID (& link) Modification* *blanks mean the assay detects the ABCE1 ATP-binding cassette sub-family E member 1 P61221 non-modified peptide sequence ABCE1 ATP-binding cassette sub-family E member 1 P61221 ABI1 Abl interactor 1 Q8IZP0 ABI1 Abl interactor 1 Q8IZP0 AKT1 RAC-alpha serine/threonine-protein kinase P31749 AKT1 RAC-alpha serine/threonine-protein kinase P31749 ANXA1 Annexin A1 P04083 ANXA4 annexin A4 P09525 ANXA5 Annexin A5 P08758 ANXA5 Annexin A5 P08758 ANXA6 annexin A6 P08133 B2M Beta-2-microglobulin P61769 B2M Beta-2-microglobulin P61769 BCAP31 B-cell receptor-associated protein 31 P51572 BCAP31 B-cell receptor-associated protein 31 P51572 BCL2 Apoptosis regulator Bcl-2 P10415 BCL2L1 Bcl-2-like protein 1 Q07817 BCL2L11 Bcl-2-like protein 11 O43521 BCL2L11 Bcl-2-like protein 11 O43521 BCL2L2 Bcl-2-like protein 2 Q92843 BCL2L2 Bcl-2-like protein 2 Q92843 BCL3 B-cell lymphoma 3 protein P20749 BCL3 B-cell lymphoma 3 protein P20749 BID BH3-interacting domain death agonist P55957 BID BH3-interacting domain death agonist P55957 BNIP3L BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like O60238 BNIP3L BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like O60238 BPGM Bisphosphoglycerate mutase P07738 BPGM Bisphosphoglycerate mutase P07738 BST2 Bone marrow stromal antigen 2 Q10589 BST2 Bone marrow stromal antigen 2 Q10589 C1QA Complement C1q subcomponent subunit A P02745 C1QA Complement C1q subcomponent
    [Show full text]
  • Mechanisms of Leukocyte Distribution During Sepsis
    Ploppa et al. Critical Care 2010, 14:R201 http://ccforum.com/content/14/6/R201 RESEARCH Open Access Mechanisms of leukocyte distribution during sepsis: an experimental study on the interdependence of cell activation, shear stress and endothelial injury Annette Ploppa1, Volker Schmidt1, Andreas Hientz2, Joerg Reutershan1, Helene A Haeberle1, Boris Nohé1* Abstract Introduction: This study was carried out to determine whether interactions of cell activation, shear stress and platelets at sites of endothelial injury explain the paradoxical maldistribution of activated leukocytes during sepsis away from local sites of infection towards disseminated leukocyte accumulation at remote sites. Methods: Human umbilical venous endothelial cells (HUVEC) and polymorphonuclear neutrophils (PMN) were activated with lipopolysaccharide at 100 and 10 ng/ml to achieve adhesion molecule patterns as have been reported from the hyper- and hypo-inflammatory stage of sepsis. To examine effects of leukocyte activation on leukocyte-endothelial interactions, activated HUVEC were perfused with activated and non-activated neutrophils in a parallel plate flow chamber. Adhesion molecule expression and function were assessed by flow cytometry and blocking antibodies. In a subset of experiments the sub-endothelial matrix was exposed and covered with platelets to account for the effects of endothelial injury. To investigate interactions of these effects with flow, all experiments were done at various shear stress levels (3 to 0.25 dyne/cm2). Leukocyte-endothelial interactions were analyzed by videomicroscopy and analysis of covariance. Results: Activation of neutrophils rendered adhesion increasingly dependent on shear stress reduction. At normal shear stress, shedding of L-selectin decreased adhesion by 56%. Increased rolling fractions of activated PMN at low shear stress revealed impaired integrin affinity despite numerical up-regulation of CD11b.
    [Show full text]